| 郑余忠,陈新国,金总敏,吴志娟,金黎攀.血脂康联合阿托伐他汀治疗对急性脑梗死患者有效性及安全性观察[J].浙江中西医结合杂志,2014,24(12): |
| 血脂康联合阿托伐他汀治疗对急性脑梗死患者有效性及安全性观察 |
| Xuezhikang and atorvastatin treatment on efficacy and safety in patients with acute cerebral infarction Zheng Yuzhong ,chen xinguo. Yonglin central hospital, Yongjia, Zhejiang ,325106, China |
| 投稿时间：2014-01-26 修订日期：2014-09-12 |
| DOI： |
| 中文关键词: 血脂康 阿托伐他汀 脑梗死 有效性 安全性 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 1388 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：观察血脂康联合阿托伐他汀治疗对急性脑梗死患者的有效性及安全性。方法：选择经确诊的脑梗死患者109例,随机分为对照组和观察组,两组患者均给予降颅内压、抗凝、改善脑循环及营养脑细胞等常规治疗措施,对照组在常规治疗的基础上予以阿托伐他汀钙20mg每晚睡前半小时口服；观察组在对照组的基础上加用血脂康600mg,一天2次,口服,均连用8周。结果：治疗后两组血脂与治疗前比较,TC、TG和LDL-C水平明显下降(p<0.01),HDL-C水平有所升高(p<0.05),且观察组较对照组下降或上升更为明显,差异均有统计学意义(p<0.05)。治疗后两组的血清hs-CRP 、NIHSS评分与治疗前比较下降明显(p<0.01),且观察组hs-CRP 、NIHSS较对照组下降更为明显,差异均有统计学意义(p<0.05)；观察组的临床总有效率明显高于对照组(x2=4.68,p<0.05)。两组治疗前后肝肾功能、肌酸激酶、肌病发生率及消化道反应发生率差异无统计学意义(p>0.05)。结论：血脂康联合阿托伐他汀治疗急性脑梗死能有效地起到强化调脂效果,血浆hs-CRP 水平及NIHSS评分明显下降,临床疗效确切,且用药安全,值的临床推广。 |
| 英文摘要: |
| Objective: To observe the effect of Xuezhikang and atorvastatin treatment effectiveness and safety on acute cerebral infarction. Methods: in 109 cases with cerebral infarction confirmed, were randomly divided into control group and observation group, two groups of patients were given to reduce intracranial pressure, anticoagulation, improve cerebral circulation and nutrition of brain cells and other conventional treatment, the control group on the basis of conventional treatment of atorvastatin calcium 20mg every night before going to bed half an hour oral; observation basic group in the control group with Xuezhikang 600mg, orally 2 times a day, for 8 weeks, all. Results: after the treatment, two groups of lipid compared with before treatment, TC, TG and LDL-C levels were significantly decreased (p<0.01), the level of HDL-C increased (p<0.05), and the observation group than in the control group decreased or increased more significantly, the differences were statistically significant (p<0.05). After treatment, serum hs-CRP, NIHSS of the two groups were significantly decreased compared with that before treatment (p<0.01), and the observation group hs-CRP, NIHSS compared with the control group decreased more significantly, the differences were statistically significant (p<0.05); clinical total effective rate of observation group was significantly higher than the control group (x2=4.68, p<0.05). The two groups before and after treatment of liver and kidney function, creatine kinase, myopathy and incidence of gastrointestinal reaction rate had no significant difference (p>0.05). Conclusion: Xuezhikang combined with atorvastatin in the treatment of acute cerebral infarction can effectively improved by regulating lipid, plasma hs-CRP level and NIHSS score decreased significantly, clinical efficacy, and drug safety, clinical value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
